Malm Camilla, Jaremko Georg, Brehmer Marianne
Department of Oncology/Pathology, Karolinska Institute, Stockholm, Sweden.
Stockholm South General Hospital, Stockholm, Sweden.
Scand J Urol. 2022 Oct-Dec;56(5-6):397-403. doi: 10.1080/21681805.2022.2107065. Epub 2022 Aug 15.
To evaluate S-phase fraction as a predictor of invasiveness and cancer-specific survival in upper tract urothelial carcinoma (UTUC).
One hundred and fifteen patients having undergone radical nephroureterectomy were analysed with histology in radical nephroureterectomy specimens as reference test and S-phase fraction as index test. Ploidy and S-phase were determined using flow cytometry. Differences in S-phase fraction were calculated between stages, grades (WHO 1999 and 2004 classifications), ploidy and patients that died of UTUC and those who did not. Five- and 10-year-cancer-specific survivals were calculated. Areas under the ROC curve (AUCs) of S-phase fraction in relation to tumour stage and to death from UTUC were measured. Multiple Cox regression was performed.
Independent prognostic markers of death from UTUC were S-phase fraction and stage. Correlation between S-phase fraction and risk of dying from UTUC was strong, with a 17% greater risk of death from UTUC with every 1% increase in S-phase fraction, hazard ratio = 1.17, 95% CI = 1.10-1.25, < 0.001, Spearman's rho = 0.65. AUCs for S-phase fraction as predictors of stage and death from UTUC were 0.8 (95% CI = 0.705-0.894) and 0.77 (95% CI = 0.67-0.87), respectively. Cancer-specific survival was statistically significantly different between stages, ploidy and WHO 1999 grades, but not between WHO 2004 grades. This was also reflected in S-phase fraction, which differed in LG-G1 compared with LG-G2 and in HG-G2 compared with HG-G3.
S-phase fraction was a good test for predicting both invasiveness and cancer-specific survival. Using both WHO 1999 and 2004 classifications, rather than one system alone, had a higher predictive value of cancer-specific survival.
评估S期分数作为上尿路尿路上皮癌(UTUC)侵袭性和癌症特异性生存预测指标的价值。
对115例行根治性肾输尿管切除术的患者进行分析,以根治性肾输尿管切除标本的组织学检查作为参考检测,S期分数作为指标检测。采用流式细胞术测定倍体和S期。计算不同分期、分级(WHO 1999年和2004年分类)、倍体以及死于UTUC和未死于UTUC患者之间S期分数的差异。计算5年和10年癌症特异性生存率。测量S期分数相对于肿瘤分期和UTUC死亡的ROC曲线下面积(AUC)。进行多因素Cox回归分析。
UTUC死亡的独立预后标志物为S期分数和分期。S期分数与UTUC死亡风险之间的相关性很强,S期分数每增加1%,UTUC死亡风险增加17%,风险比=1.17,95%可信区间=1.10-1.25,P<0.001,Spearman相关系数=0.65。S期分数作为分期和UTUC死亡预测指标的AUC分别为0.8(95%可信区间=0.705-0.894)和0.77(95%可信区间=0.67-0.87)。不同分期、倍体和WHO 1999分级之间的癌症特异性生存存在统计学显著差异,但WHO 2004分级之间无差异。这也反映在S期分数上,LG-G1与LG-G2相比以及HG-G2与HG-G3相比存在差异。
S期分数是预测侵袭性和癌症特异性生存的良好检测指标。同时使用WHO 1999年和2004年分类,而非仅使用一个系统,对癌症特异性生存具有更高的预测价值。